If you or a loved one were diagnosed with Urothelial Carcinoma or Transitional Cell Carcinoma (TCC) after taking Zantac (Ranitidine), you may be entitled to recover compensation from a Zantac Urothelial Carcinoma lawsuit or settlement.
A team of heartburn drug injury lawyers and class action attorneys is investigating potential lawsuit and settlement cases of individuals who claim to have been diagnosed with urothelial carcinoma or transitional cell carcinoma (TCC) after taking Zantac or Ranitidine.
Urothelial carcinoma (UCC) or transitional cell carcinoma (TCC) is a type of cancer that develops in urothelial cells or transitional epithelium cells (specialized cells that line the inside of the bladder and other hollow parts of the urinary tract such as the urethra, ureters, and renal pelvis that form a barrier known as the epithelium) that grow out of control and form a cancerous mass called a tumor.
Urothelial carcinoma is the most common form of bladder cancer, accounting for about 90% of all bladder cancers. Transitional cell carcinoma also accounts for about 10-15 percent of adult kidney cancers.
Zantac Urothelial Carcinoma & Transitional Cell Carcinoma (TCC) Cancer Lawsuit Cases
Zantac urothelial carcinoma lawsuit and settlement cases potentially being investigated include claims of individuals who took ranitidine or Zantac that was the subject of a recall and suffered serious injuries, side-effects or complications including, among others:
- Urothelial carcinoma (UCC)
- Transitional cell carcinoma (TCC)
- Invasive urothelial carcinoma
- Invasive transitional cell carcinoma
- Infiltrating urothelial carcinoma
- Papillary carcinoma
- Flat carcinomas
Papillary carcinomas (also known as papillary urothelial neoplasms, papillary tumors or papillary lesions) are thin finger-like or warty projections on the inner part of the bladder wall that grow towards the middle of the bladder. Flat carcinomas (flat lesions) originate within the mucosa and do not project out from the walls of the bladder. Papillary carcinomas and flat carcinomas that remain in the inner layer of bladder cells and do not grow into the deeper layers are known as non-invasive papillary carcinomas or non-invasive flat carcinomas (or flat carcinoma in situ). Most urothelial carcinomas are non-invasive papillary carcinomas. Those that grow into the deep layers of the bladder are known as invasive urothelial carcinomas or invasive transitional cell carcinomas.
Urothelial carcinoma subtypes can also include variants such as:
- Plasmacytoid urothelial carcinoma
- Signet ring urothelial carcinoma
- Diffuse urothelial carcinoma
- Nested urothelial carcinoma
- Micropapillary urothelial carcinoma
- Lipoid cell urothelial carcinoma
- Sarcomatoid urothelial carcinoma
- Microcystic urothelial carcinoma
- Lymphoepithelioma-like urothelial carcinoma
- Inverted papilloma-like urothelial carcinoma
- Clear cell urothelial carcinoma (glycogen rich)
- Giant cell urothelial carcinoma
- Poorly differentiated urothelial carcinoma
- Lipid rich urothelial carcinoma
If you or someone you love took Zantac or Ranitidine and have suffered from Urothelial Carcinoma or Transitional Cell Carcinoma (TCC), you may be entitled to compensation from a Zantac Urothelial Carcinoma lawsuit case or settlement claim. Contact a drug injury lawyer to request a free case review.
*If you or a loved one are experiencing health issues, side effects or complications after taking a prescription drug or medication, we urge you to promptly consult with your doctor or physician for an evaluation.
**The listing of a company (e.g., Sandoz, Sanofi, Apotex, Perrigo, Lannett or Novitium) or product (e.g., Zantac or Ranitidine) is not meant to state or imply that the company acted illegally or improperly or that the product is unsafe or defective; rather only that an investigation may be, is or was being conducted to determine whether legal rights have been violated.
***The use of any trademarks, tradenames or service marks is solely for product identification and/or informational purposes.
Fill out the form on the right for a free attorney review